Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VQW-765 · 2 trials · 2 indications
Subjective Units of Distress Scale (SUDS) during performance phase, scored from 0-100 with a higher score indicating higher distress.
| Arm | Type | Description |
|---|---|---|
| VQW-765 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| VQW-765 | DRUG | oral capsule |
| Placebo | DRUG | oral capsule |
Inclusion Criteria: 1. Ability and willingness to provide written informed consent. 2. Male and female subjects aged 18-65 years, inclusive. 3. Current diagnosis of social anxiety disorder. 4. Liebowitz Social Anxiety Scale total score ≥60. 5. Public Speaking Anxiety Scale total score ≥60. 6. Hamil...
VQW-765 is an investigational small molecule being developed for the on-demand treatment of Social Anxiety Disorder (SAD) and Performance Anxiety. It is currently in clinical development and has not been approved by the FDA.
VQW-765 is being developed by Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). The company is conducting clinical trials to evaluate the drug's efficacy and safety for anxiety-related conditions.
VQW-765 has completed a Phase 2 trial for Performance Anxiety and is currently in a Phase 3 trial for Social Anxiety Disorder. The Phase 3 study is active but not recruiting participants.
VQW-765 has two clinical trials: NCT04800237, a completed Phase 2 study in Performance Anxiety with 230 participants, and NCT07221578, an active Phase 3 study in Social Anxiety Disorder with 500 participants. Both trials are placebo-controlled and double-blind.
No alternative names for VQW-765 have been reported. It is identified solely by its investigational code name in clinical trials and public records.